ATE115410T1 - Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind. - Google Patents

Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.

Info

Publication number
ATE115410T1
ATE115410T1 AT90908772T AT90908772T ATE115410T1 AT E115410 T1 ATE115410 T1 AT E115410T1 AT 90908772 T AT90908772 T AT 90908772T AT 90908772 T AT90908772 T AT 90908772T AT E115410 T1 ATE115410 T1 AT E115410T1
Authority
AT
Austria
Prior art keywords
fibrin
plasminogen
plasminogen activator
fragments
thrombus
Prior art date
Application number
AT90908772T
Other languages
English (en)
Inventor
Andrei Z Budzynski
Linda C Knight
Ahmed Ak Hasan
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Application granted granted Critical
Publication of ATE115410T1 publication Critical patent/ATE115410T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT90908772T 1989-05-24 1990-05-21 Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind. ATE115410T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35697889A 1989-05-24 1989-05-24

Publications (1)

Publication Number Publication Date
ATE115410T1 true ATE115410T1 (de) 1994-12-15

Family

ID=23403780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90908772T ATE115410T1 (de) 1989-05-24 1990-05-21 Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.

Country Status (7)

Country Link
US (1) US5288490A (de)
EP (1) EP0473689B1 (de)
JP (1) JPH04505326A (de)
AT (1) ATE115410T1 (de)
CA (1) CA1335361C (de)
DE (1) DE69015182T2 (de)
WO (1) WO1990014102A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001355A (en) * 1982-12-14 1999-12-14 Dowdle; Eugene Bernard Davey Pro-tPA for the treatment of thrombosis, embolism and related conditions
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US6599515B1 (en) * 1995-01-16 2003-07-29 Baxter International Inc. Fibrin porous structure
US5951981A (en) * 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6605115B1 (en) * 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
EP1130031A1 (de) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Verfahren zur Hemmung der Angiogenese unter Verwendung von Molekülen die die Plasminbildung steigern oder die Plasminaktivität verlängern
US6989164B2 (en) * 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
EP1380290A1 (de) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
JP4471867B2 (ja) * 2005-02-25 2010-06-02 シスメックス株式会社 Ｄダイマー測定用標準物質
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
WO2007008073A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
AU2006267176A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
FR2979635B1 (fr) * 2011-09-07 2015-03-20 Hyphen Biomed Procede de dosage du plasminogene en milieu liquide, compositions et kit associes.
DE102014112212A1 (de) 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
JP7028904B2 (ja) * 2019-03-21 2022-03-02 アカデミア シニカ 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用
CN119185519A (zh) * 2023-06-27 2024-12-27 广东粤港澳大湾区国家纳米科技创新研究院 靶向药物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4536391A (en) * 1982-11-17 1985-08-20 Otsuka Pharmaceutical Co. Process for preparing urokinase complex
SU1128601A1 (ru) * 1983-05-10 1985-07-15 Всесоюзный кардиологический научный центр АМН СССР Урокиназа,иммобилизированна на фибриногене
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates

Also Published As

Publication number Publication date
EP0473689A4 (en) 1992-07-15
DE69015182T2 (de) 1995-05-24
JPH04505326A (ja) 1992-09-17
CA1335361C (en) 1995-04-25
WO1990014102A1 (en) 1990-11-29
EP0473689B1 (de) 1994-12-14
EP0473689A1 (de) 1992-03-11
US5288490A (en) 1994-02-22
DE69015182D1 (de) 1995-01-26

Similar Documents

Publication Publication Date Title
ATE115410T1 (de) Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.
Stamler et al. S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme.
Collen et al. The fibrinolytic system in man
Plow et al. Plasminogen receptors in the mediation of pericellular proteolysis
SE8800238D0 (sv) Flytande enzymkompositioner
Smith et al. Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin αIIbβ3 (∗)
DK0973806T3 (da) Sted-beskyttet proteinmodificering
Fears Binding of plasminogen activators to fibrin: characterization and pharmacological consequences
AU7168591A (en) Hybrid protein c
Urano et al. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity
ES494343A0 (es) Procedimiento de obtencion de un activador del plasminogeno
EP0356836A3 (en) Thrombin-binding substance and process for preparing the same
EP0290118A3 (de) Fibrinolytisch wirksames Enzym
Liang et al. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs
Rijken et al. Interaction of plasminogen activators and plasminogen with heparin: effect of ionic strength
Okada et al. Effects of fibrin and α2‐antiplasmin on plasminogen activation by staphylokinase
Loscalzo An overview of thrombolytic agents
ES8603951A1 (es) Un metodo de estabilizar el zimogeno de uroquinasa
Sakharov et al. Two-step targeting of urokinase to plasma clot provides efficient fibrinolysis
KR900004351A (ko) 하이브리드 단일클론 항체, 그의 제조방법 및 용도
Robinson et al. Slow clearance of acylated, hybrid thrombolytic enzymes
Grinenko et al. Plasminogen-binding centers of molecules of fibrinogen, fibrin and products of their proteolysis
Lijnen et al. 282 Functional properties of chimaeric molecules containing structural domains of tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA)
Kawamura et al. The effects of polysaccharides on plasminogen activation by single chain-and two chain-tissue plasminogen activator
Bode et al. Antibody-Mediated Thrombolysis: Promise and Problems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties